WebNews

Please enter a web search for web results.

NewsWeb

The Manila Times
manilatimes. net > 04/09/2026 > tmt-newswire > globenewswire > livtech-acquires-alora-healthcare-systems-further-expanding-leadership-in-home-based-care-technology > 2317349

Liv Tech Acquires Alora Healthcare Systems, Further Expanding Leadership in Home-Based Care Technology

1+ week, 1+ day ago  (343+ words) The demand for home-based care continues to surge-with the global market projected to exceed $300 billion. This expected growing demand, along with unprecedented pressure from staffing shortages, evolving regulatory mandates, and the shift toward value-based reimbursement, has helped introduce extraordinary opportunities…...

The Manila Times
manilatimes. net > 04/18/2026 > tmt-newswire > globenewswire > cardiff-oncology-presents-preclinical-data-on-its-plk1-inhibitor-onvansertib-in-combination-with-a-her2-targeted-adc-at-the-2026-aacr-annual-meeting > 2323053

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

14+ hour, 53+ min ago  (378+ words) Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination…...

The Manila Times
manilatimes. net > 04/18/2026 > tmt-newswire > globenewswire > boundless-bio-presents-preclinical-breast-cancer-data-from-its-oral-kinesin-degrader-program-at-2026-aacr-annual-meeting > 2323084

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

13+ hour, 52+ min ago  (80+ words) Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Title: Selective degradation of a novel kinesin as a potential therapeutic strategy addressing high-risk…...

The Manila Times
manilatimes. net > 04/15/2026 > tmt-newswire > globenewswire > alira-health-and-autoimmune-neurology-alliance-aina-launch-axis-registry-advancing-real-world-and-patient-centered-research-in-autoimmune-neurology > 2321061

Alira Health and Autoimmune Neurology Alliance (Ai NA) Launch AXIS Registry, Advancing Real-World and Patient-Centered Research in Autoimmune Neurology

2+ day, 21+ hour ago  (110+ words) New registry connects patients and researchers to accelerate understanding and improve care in autoimmune neurological diseases FRAMINGHAM, Mass. , April 15, 2026 (GLOBE NEWSWIRE) -- Alira Health, in partnership with the Autoimmune Neurology Alliance (Ai NA), today announced the launch of the AXIS Registry,…...

The Manila Times
manilatimes. net > 04/15/2026 > tmt-newswire > globenewswire > us-news-world-report-names-entire-all-seasons-senior-living-portfolio-best-of-the-best > 2321262 > amp

U. S. NEWS & WORLD REPORT NAMES ENTIRE ALL SEASONS SENIOR LIVING PORTFOLIO 'BEST OF THE BEST

2+ day, 19+ hour ago  (212+ words) Beztak is proud to announce'that the entire portfolio of 'All Seasons Senior Living communities have been recognized as the "Best of the Best" by U. S. News & World Report. All Seasons earned top distinction in the 2026 U. S. News Best Senior Living ratings among…...

The Manila Times
manilatimes. net > 04/16/2026 > tmt-newswire > globenewswire > the-association-for-frontotemporal-degeneration-aftd-hosts-first-capitol-hill-briefing-frontotemporal-degeneration-shining-a-light-on-a-little-known-dementia > 2321379 > amp

The Association for Frontotemporal Degeneration (AFTD) Hosts First Capitol Hill Briefing: 'Frontotemporal Degeneration: Shining a Light on a Little-Known Dementia

2+ day, 15+ hour ago  (116+ words) The event brought together Hill staffers with caregivers, advocates, researchers, and federal leaders to raise awareness of frontotemporal degeneration (FTD) and highlight the urgent need for greater investment in research and support services. Advocate Emma Heming Willis delivers prepared remarks…...

The Manila Times
manilatimes. net > 04/15/2026 > tmt-newswire > globenewswire > filana-therapeutics-announces-publication-in-epilepsia-of-preclinical-simufilam-data > 2320905

Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data

2+ day, 22+ hour ago  (363+ words) The study evaluated simufilam in the Tsc1-c KO mouse, an exceptionally severe and rapidly progressive model of TSC-related epilepsy. In this model, seizures normally worsen steadily over time. Epilepsia paper, Figure 3 C Heatmap of the daily number of seizures per…...

The Manila Times
manilatimes. net > 04/16/2026 > tmt-newswire > globenewswire > shingles-raises-heart-and-stroke-risk-protect-yourself-with-vaccination > 2321372

Shingles Raises Heart and Stroke Risk: Protect Yourself with Vaccination

2+ day, 15+ hour ago  (476+ words) NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- (Feature Impact)Shingles isn't just a painful rash and nerve pain. It's also linked with a higher risk of serious cardiovascular events, including heart attack and stroke, especially in the weeks to months after infection....

The Manila Times
manilatimes. net > 04/15/2026 > tmt-newswire > globenewswire > nexalin-advances-fda-alzheimers-strategy-following-landmark-leadership-meetings-in-the-us-and-china > 2321178

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U. S. and China

2+ day, 20+ hour ago  (214+ words) The high-level meetings brought together Nexalin leadership, American-based academic research teams and members of the international Alzheimer's clinical community. Insights gained from these discussions are directly informing Nexalin's FDA strategy and shaping the final design of its upcoming FDA clinical…...

The Manila Times
manilatimes. net > 04/14/2026 > tmt-newswire > globenewswire > myriad-genetics-expands-access-for-mychoice-test-to-prostate-cancer-patients-in-japan > 2320142

Myriad Genetics Expands Access for My Choice Test to Prostate Cancer Patients in Japan

3+ day, 21+ hour ago  (489+ words) The Manila Times Myriad Genetics Expands Access for My Choice Test to Prostate Cancer Patients in Japan SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that…...